HTA Pathways & Real-World Evidence

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, health economist, and it's great to have you with us today.

SaraAnd I'm Sara, market access strategy. Always good to be here — and I'll say, I've had today's topics circled since this morning.

MarcusSame here. We're looking at CMS Part D Redesign implementation updates — reshaping chronic therapy access models. Then ICER's final evidence report on Alzheimer's disease therapies — a critical moment for disease-modifying treatments. Plus EMA's new adaptive pathway for rare diseases — signaling shifts in ultra-orphan evidence generation. And FDA Breakthrough Therapy designation expansion with HEOR implications.

SaraThat second one, the ICER report, is particularly interesting to me — the budget impact question for Alzheimer's therapies has been a sticking point for payers globally, and I'm curious how they frame it now.

MarcusExactly. Let's get into it.

MarcusThe CMS Part D Redesign is now fully operational, and we're seeing initial data on how inflation rebates and benefit design changes affect chronic therapy access. The focus is on reducing out-of-pocket costs for patients, but I'm curious about the system-level impact.

SaraExactly, and what strikes me is the fundamental shift from manufacturer rebates to patient cost-sharing. That changes how we approach value. But I wonder if the data we're seeing captures the full picture of patient adherence and system costs.

MarcusThat's a fair point. Initial reports suggest reduced premiums, but long-term budget implications remain unclear. What's interesting is how this redesign forces re-evaluation of evidence generation for chronic conditions.

SaraI'd push back slightly — it's not just evidence generation, but how we present evidence addressing new cost-sharing structures. Payers are now laser-focused on adherence and total cost of care, which fundamentally alters the value proposition.

MarcusThat connects to something I keep coming back to: the need for HEOR models incorporating patient behavior in response to financial incentives. This redesign is essentially a natural experiment in that.

SaraRight, and from the payer side, we're seeing more requests for models simulating different cost-sharing scenarios. It's methodologically challenging but necessary adaptation.

MarcusThe part that gives me pause is potential unintended consequences. If patients face higher costs, we might see reduced necessary therapy utilization, increasing downstream costs.

SaraThat's precisely what CMS is monitoring. They're using real-world data to assess if the redesign achieves goals without compromising care quality.

SaraICER's final evidence report on Alzheimer's disease therapies is out, and they've maintained their previous stance on the evidence base. They're calling for more real-world data on long-term outcomes — a significant hurdle for these therapies.

MarcusThat's one read — I'd frame it slightly differently. What I see is ICER balancing hope for disease-modifying treatments with uncertainty about long-term benefits. They're not saying these drugs don't work, but that evidence isn't robust enough for traditional cost-effectiveness analysis.

SaraWhat strikes me about that is the budget impact question. Even if effective, per-patient costs are enormous, and budget impact for health systems is unsustainable without price adjustments or risk-sharing.

MarcusThat's fair, though I think payers would see it differently. They're concerned about opportunity cost — diverting resources from other areas. ICER highlights current evidence doesn't justify price tags aligned with value.

SaraThe part that gives me pause is the timeline. How long do we wait for real-world data? Patients are progressing now, and every access delay has a cost. That tension remains unresolved.

MarcusExactly. And I wonder if that's the full picture though. FDA accelerated approvals were based on surrogate endpoints, confirmatory trials ongoing. ICER essentially says we need more evidence before assessing value.

SaraBut market access requires working with available evidence. That means developing innovative pricing models accounting for uncertainty and long-term outcomes.

MarcusThe EMA has announced a new adaptive pathway for rare diseases, aiming to speed development through flexible trial designs. This represents a significant shift from traditional stepwise approaches.

SaraThat's interesting, and I'm curious about HTA implications. If regulatory pathways become more adaptive, how do HTA bodies assess evidence? They typically require robust data, and adaptive designs may raise validity questions.

MarcusWhat's striking here is the focus on ultra-orphan conditions. The pathway allows earlier access based on preliminary data but requires post-marketing studies. It's a balance between innovation and evidence.

SaraI'd push back slightly. Payer concern is uncertainty around long-term outcomes. If approved via adaptive trials, real-world evidence might not match expectations, leading to budget overruns.

MarcusThat connects to something I keep coming back to: need for closer regulatory-HTA collaboration in rare diseases. EMA signals flexibility, but HTA frameworks may not be ready to adjust.

SaraRight, and from payer side, we're seeing more risk-sharing requests in rare diseases — a response to evidence uncertainty, but complicating market access.

MarcusThe part that gives me pause is global harmonization. If EMA leads with adaptive designs, will other agencies follow? Could create patchwork of evidence requirements.

SaraFDA has expanded Breakthrough Therapy designation to include more diseases and criteria. This could accelerate development but raises questions about HTA evidence requirements.

MarcusThat's one read — I'd frame it slightly differently. What I see is FDA addressing unmet needs more quickly, but designation itself doesn't change HTA evidence requirements. It's about development speed, not evidence quality.

SaraWhat strikes me is potential misalignment. If a drug gets Breakthrough status based on preliminary data, payers may still require robust evidence for reimbursement, causing access delays.

MarcusThat's fair, though I think payers would see it differently. They're concerned about evidence quality, not just development speed. Breakthrough designation is regulatory, not value endorsement.

SaraThe part that gives me pause is impact on HEOR strategies. Companies might invest more in real-world evidence for Breakthrough therapies, but that could be resource-intensive.

MarcusExactly. And I wonder if that's the full picture though. Expansion might lead to earlier HTA engagement, streamlining assessment processes.

SaraThat's a point. Some companies use designation to initiate early payer dialogues, aligning evidence generation with value assessment needs.

SaraA lot to think about today. I'll be watching how the CMS Part D redesign plays out for chronic therapies in the coming months.

MarcusSame — and for me the thread running through today is the growing tension between accelerated regulatory pathways and traditional HTA evidence requirements. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.